Alyeska Investment Group
VRDN icon

Alyeska Investment Group’s Viridian Therapeutics VRDN Stock Holding History

Alyeska Investment Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$1.3M – 692
2024
Q2 		$1.3M Hold
100,000
– – 0.01% 446
2024
Q1 		$1.75M Buy
+100,000
New +$1.94M 0.01% 381
2020
Q2 		– Sell
-49,560
Closed -$563K – 578
2020
Q1 		$332K Buy
+49,560
New +$577K 0.01% 340

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alyeska Investment Group's VRDN Position: Q3 2024 in Review

Alyeska Investment Group sold out of Viridian Therapeutics (VRDN) in Q3 2024, closing a stake of 100,000 shares — an estimated $1.3M sold.

Alyeska Investment Group first reported a position in VRDN in Q1 2020 and held it in 3 quarters. The position peaked at $1.75M in Q1 2024. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Alyeska Investment Group reported no remaining Viridian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 100,000 Viridian Therapeutics shares in Q3 2024, an estimated $1.3M.
  • Alyeska Investment Group first reported a position in Viridian Therapeutics in Q1 2020 and held it in 3 quarters.
  • Alyeska Investment Group's Viridian Therapeutics position peaked at $1.75M in Q1 2024.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.